Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Ascentage Files China NDA for 3rd-Gen BCR-ABL Inhibitor

publication date: Jun 18, 2020

Ascentage Pharma of Suzhou has submitted an NDA to China's Center for Drug Evaluation for HQP135, its third-generation BCR-ABL inhibitor, as a treatment for leukemia. The candidate is specifically designed to treat chronic myeloid leukemia (CP-CML) and accelerated phase CML (AP-CML) that has developed the T315I mutation, which is the most common drug-resistant mutation caused by BCR-ABL drugs such as Gleevec. The submission for HQP135 is the first NDA that Ascentage has submitted to regulators. More details....

Stock Symbol: (HK: 6855)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.